TGFB1 and focal segmental glomerulosclerosis: It has been shown that treatment with Pirfenidone, a non-specific antifibrotic effect of TGF-β, can improve eGFR in the trials of DN and focal segmental glomerulosclerosis (FSGS) (Lancaster et al., 2017).